We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amgen and UCB announced results from a Phase III trial that showed romosozumab significantly reduced the incidence of new vertebral fractures in postmenopausal women with osteoporosis through 12 and 24 months, meeting the study's co-primary endpoints. Read More
The FDA faces a significant number of security vulnerabilities that threaten the confidentiality and integrity of its industry and public health data, a congressional watchdog said. Read More
Drug manufacturers are pressing for faster approval of antimicrobial susceptibility tests, because without them, physicians are reluctant to prescribe new antibiotic drugs, even when they have received FDA approval. Read More